ELMD Quote, Financials, Valuation and Earnings

IRIDEX has a net margin of 12.11% compared to Electromed's net margin of -16.69%. Electromed's return on equity of 15.91% beat IRIDEX's return on equity of -157.91%.

Electromed has a consensus price target of $37.00, signalling upside risk potential of 66.14%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 73.91%. Given that IRIDEX has higher upside potential than Electromed, analysts believe IRIDEX is more attractive than Electromed.

Electromed has a beta of 0.460, which suggesting that the stock is 53.993% less volatile than S&P 500. In comparison IRIDEX has a beta of 0.692, suggesting its less volatile than the S&P 500 by 30.819%.

Electromed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Electromed pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

Electromed quarterly revenues are $16.3M, which are larger than IRIDEX quarterly revenues of $11.6M. Electromed's net income of $2M is higher than IRIDEX's net income of -$1.9M. Notably, Electromed's price-to-earnings ratio is 29.69x while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Electromed is 3.34x versus 0.39x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

Modular Medical has a net margin of 12.11% compared to Electromed's net margin of --. Electromed's return on equity of 15.91% beat Modular Medical's return on equity of --.

Electromed has a consensus price target of $37.00, signalling upside risk potential of 66.14%. On the other hand Modular Medical has an analysts' consensus of $8.00 which suggests that it could grow by 700%. Given that Modular Medical has higher upside potential than Electromed, analysts believe Modular Medical is more attractive than Electromed.

Electromed has a beta of 0.460, which suggesting that the stock is 53.993% less volatile than S&P 500. In comparison Modular Medical has a beta of -4.845, suggesting its less volatile than the S&P 500 by 584.542%.

Electromed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Modular Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Electromed pays -- of its earnings as a dividend. Modular Medical pays out -- of its earnings as a dividend.

Electromed quarterly revenues are $16.3M, which are larger than Modular Medical quarterly revenues of --. Electromed's net income of $2M is higher than Modular Medical's net income of -$4.8M. Notably, Electromed's price-to-earnings ratio is 29.69x while Modular Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Electromed is 3.34x versus -- for Modular Medical. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of 12.11% compared to Electromed's net margin of -2.16%. Electromed's return on equity of 15.91% beat Myomo's return on equity of -48.64%.

Electromed has a consensus price target of $37.00, signalling upside risk potential of 66.14%. On the other hand Myomo has an analysts' consensus of $9.05 which suggests that it could grow by 182.81%. Given that Myomo has higher upside potential than Electromed, analysts believe Myomo is more attractive than Electromed.

Electromed has a beta of 0.460, which suggesting that the stock is 53.993% less volatile than S&P 500. In comparison Myomo has a beta of 1.633, suggesting its more volatile than the S&P 500 by 63.336%.

Electromed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Electromed pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Electromed quarterly revenues are $16.3M, which are larger than Myomo quarterly revenues of $12.1M. Electromed's net income of $2M is higher than Myomo's net income of -$260.1K. Notably, Electromed's price-to-earnings ratio is 29.69x while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Electromed is 3.34x versus 3.71x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of 12.11% compared to Electromed's net margin of -118.53%. Electromed's return on equity of 15.91% beat Stereotaxis's return on equity of -139.2%.

Electromed has a consensus price target of $37.00, signalling upside risk potential of 66.14%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 111.27%. Given that Stereotaxis has higher upside potential than Electromed, analysts believe Stereotaxis is more attractive than Electromed.

Electromed has a beta of 0.460, which suggesting that the stock is 53.993% less volatile than S&P 500. In comparison Stereotaxis has a beta of 1.461, suggesting its more volatile than the S&P 500 by 46.088%.

Electromed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Electromed pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Electromed quarterly revenues are $16.3M, which are larger than Stereotaxis quarterly revenues of $6.3M. Electromed's net income of $2M is higher than Stereotaxis's net income of -$7.5M. Notably, Electromed's price-to-earnings ratio is 29.69x while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Electromed is 3.34x versus 6.74x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.